Donepezil can cause insomnia, vivid dreams, or nightmares, especially when taken at night or after a dose increase. Ask the prescriber whether moving the same once-daily dose to morning is appropriate. Donepezil is a medicine approved for mild, moderate, and severe dementia of the Alzheimer's type. The evidence about sleep effects therefore applies chiefly to people with Alzheimer's disease.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How common are sleep problems?
- Does morning dosing improve sleep?
- Did the problem follow a dose increase?
- What details should you bring to the discussion?
- How certain is the evidence?
How common are sleep problems?
The current U.S. label lists insomnia among donepezil's common adverse reactions and directs patients to take it in the evening, just before retiring. In pooled trials involving mild-to-moderate Alzheimer's disease, insomnia affected 9% of donepezil recipients and 6% of placebo recipients.
Abnormal dreams occurred in 3% of people receiving donepezil and none receiving placebo, according to the U.S. National Library of Medicine's DailyMed label. These differences suggest a medication effect in some people, but they cannot establish the cause of one person's symptoms.
Does morning dosing improve sleep?
Limited research supports asking about morning dosing. A 2005 case series described eight people with Alzheimer's disease whose nightmares were linked to evening donepezil; none reported nightmares after switching to morning dosing. Because the report was small and uncontrolled, it does not prove that switching will work for everyone.
Stronger evidence comes from a study of 92 people with mild-to-moderate Alzheimer's disease. After eight weeks, participants randomized from nighttime to morning donepezil reported better sleep quality and less daytime drowsiness, according to the study's PubMed record. The NHS also advises that people who experience bad dreams or difficulty sleeping may take donepezil in the morning instead. The practical question is whether the prescriber recommends moving the dose time—not changing the prescribed once-daily dose—under the NHS guidance.
Did the problem follow a dose increase?
Tell the prescriber if insomnia began or worsened after an increase from 5 mg to 10 mg. In label data, insomnia occurred in 14% of patients who increased after one week, compared with 6% among those whose increase followed six weeks at 5 mg.
That difference makes the timing of dose escalation relevant. It does not show that every patient should increase more slowly, but it gives the prescriber a specific issue to review. Ask:.
- Could the recent increase be contributing to the sleep problem?
- Does the timing of the increase matter in this case?
- Should the current dose, titration schedule, or dosing time be reviewed?
- If the dose moves to morning, exactly when should the change begin?
What details should you bring to the discussion?
Record a short timeline showing when donepezil is taken and what happens overnight. Concrete details help distinguish trouble falling asleep from vivid dreams, nightmares, repeated waking, or next-day drowsiness.
Include: Ask for precise instructions before moving the schedule. In particular, confirm how to make the transition without accidentally taking doses too close together or skipping one unintentionally.
- The current dose and usual administration time
- The date of the last dose increase
- When the sleep symptoms began
- The type and frequency of the symptoms
- Whether daytime drowsiness also changed
How certain is the evidence?
The evidence supports a conversation about timing, not a guarantee that morning dosing will solve the problem. The case series was very small, while the 92-person study relied on self-rated sleep outcomes.
An unusually high rate appeared in a small crossover trial involving posterior cortical atrophy attributed to presumed Alzheimer's disease: 44% experienced nightmares or vivid dreams during donepezil treatment, versus none during placebo alone. That particularly susceptible subgroup cannot establish the expected rate for typical Alzheimer's disease.
